155 related articles for article (PubMed ID: 35880438)
1. Investigation of
Cevik M; Namal E; Sener ND; Koksal UI; Cagatay P; Deliorman G; Ciftci C; Karaalp A; Susleyici B
Per Med; 2022 Sep; 19(5):435-444. PubMed ID: 35880438
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
3. The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
Yousef AM; Zawiah M; Al-Yacoub S; Kadi T; Tantawi DA; Al-Ramadhani H
Cancer Chemother Pharmacol; 2018 Aug; 82(2):237-243. PubMed ID: 29845393
[TBL] [Abstract][Full Text] [Related]
4. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
5. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
6. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
[TBL] [Abstract][Full Text] [Related]
7.
Khalij Y; Belaid I; Chouchane S; Amor D; Omezzine A; Ben Rejeb N; Ben Ahmed S; Bouslama A
J Chemother; 2023 Sep; 35(5):425-434. PubMed ID: 36137946
[TBL] [Abstract][Full Text] [Related]
8. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
9. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients.
Gajjar KK; Vora HH; Kobawala TP; Trivedi TI; Ghosh NR
Int J Biol Markers; 2018 May; 33(2):180-188. PubMed ID: 29799355
[TBL] [Abstract][Full Text] [Related]
12. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
[TBL] [Abstract][Full Text] [Related]
13. TYMS and DPYD polymorphisms in a Turkish population.
Süzen HS; Yüce N; Güvenç G; Duydu Y; Erke T
Eur J Clin Pharmacol; 2005 Dec; 61(12):881-5. PubMed ID: 16328315
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
[TBL] [Abstract][Full Text] [Related]
17. DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients.
Amirfallah A; Kocal GC; Unal OU; Ellidokuz H; Oztop I; Basbinar Y
J Pers Med; 2018 Dec; 8(4):. PubMed ID: 30551678
[TBL] [Abstract][Full Text] [Related]
18. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
Rumiato E; Boldrin E; Amadori A; Saggioro D
Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
[TBL] [Abstract][Full Text] [Related]
19. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
Afzal S; Gusella M; Jensen SA; Vainer B; Vogel U; Andersen JT; Brødbæk K; Petersen M; Jimenez-Solem E; Adleff V; Budai B; Hitre E; Láng I; Orosz E; Bertolaso L; Barile C; Padrini R; Kralovánszky J; Pasini F; Poulsen HE
Pharmacogenomics; 2011 Sep; 12(9):1257-67. PubMed ID: 21919605
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]